Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH

Trial Profile

Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2013

At a glance

  • Drugs Fexapotide (Primary) ; Finasteride
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2013 Pooled analysis presented at the 28th Congress of the European Association of Urology.
    • 25 May 2010 3-year follow-up results reported in a Nymox Pharmaceuticals media release.
    • 18 May 2010 A 3-year follow-up of patients from this trial is nearing completion according to a Nymox Pharmaceuticals media release; final results are expected to be available in the next two weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top